NCT01635790View on ClinicalTrials.gov

Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2016

Conditions
Diabetic Macular Edema
Interventions
DRUG

Ranibizumab

0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months

DRUG

Bevacizumab

1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months

Trial Locations (1)

1105 AZ

RECRUITING

Academic Medical Center, Dept. Ophthalmology,, Amsterdam

Sponsors

Collaborators (1)

Erasmus Medical Center
All Listed Sponsors
collaborator

University Medical Center Groningen

OTHER

collaborator

Free University Medical Center

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Radboud University Medical Center

OTHER

collaborator

Leiden University Medical Center

OTHER

collaborator

UMC Utrecht

OTHER

lead

Prof. dr. R.O. Schlingemann

OTHER

NCT01635790 - Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME) | Biotech Hunter | Biotech Hunter